Amphastar Pharmaceuticals (AMPH) 2024 Wells Fargo Healthcare Conference summary

Business strategy and capabilities

• Science-driven development leverages in-house expertise for complex generics, branded, and biologic products, with a focus on vertical integration and quality systems for supply reliability and differentiation.

• Preference for in-house development over outsourcing to maintain control and efficiency, with a toolbox of skills built over a decade.

• Strategic focus on products difficult to genericize, especially in endocrinology and intranasal/injectable/inhalable forms.

• Dual growth strategy combines organic pipeline development with targeted acquisitions, supported by a fully integrated business model across R&D, manufacturing, and distribution.

• Shift toward proprietary and biosimilar products, projected to comprise 85% of the pipeline by 2025, up from 37% in 2021.

Branded product performance and commercialization

• Baqsimi showed strong performance, with a smooth transition from Lilly, expanded distribution in the US and Europe, and is expected to reach $250–275 million in global sales.

• Dedicated contract sales force in the US, scalable model, and profitable growth focus, with international distribution relying on third-party agreements.

• Primatene Mist experienced 38% Q2 growth, normalizing to mid-single digit annual growth, driven by advertising and unit sales, with expansion into China targeting higher-end consumers.

• Product diversification has reduced reliance on legacy products, with new launches such as Primatene Mist and Baqsimi contributing to a broader revenue base.

• BAQSIMI® is expected to add $0.12–$0.18 incremental adjusted EPS in 2023 and $2.00–$2.50 at peak, with net economic benefit recognized as distribution transitions from Lilly.

Market dynamics and growth opportunities

• Glucagon market remains underpenetrated, with recent growth from 10% to 11% penetration among insulin users.

• Key product launches and filings include Albuterol (Q3 2024), Rextovy (Q2 2024), and multiple ANDA/BLA submissions for insulin, GLP-1, and intranasal products, with several regulatory milestones expected in 2024–2025.

• Shortages in complex generics (e.g., epinephrine, dextrose, sodium bicarbonate) provide ongoing opportunities due to supply reliability.

• Growth drivers for 2024 include increased promotion of Baqsimi, expanded market opportunities for the Glucagon Injection Kit, and advertising for Primatene Mist.

• Amphastar’s proprietary and branded products, including Primatene Mist and Baqsimi, are positioned as key growth engines in the evolving healthcare landscape.